Literature DB >> 7731518

In vitro growth inhibition of growth factor-stimulated meningioma cells by calcium channel antagonists.

R L Jensen1, T C Origitano, Y S Lee, M Weber, R D Wurster.   

Abstract

Studies have shown that a majority of meningiomas contain receptors for platelet-derived growth factor and epidermal growth factor and that these growth factors promote the proliferation of meningioma cells in culture. Although the mechanism of action has not been elucidated, intracellular calcium appears to be part of the signal transduction mechanism. Because alterations in intracellular calcium could interrupt this pathway and decrease cellular proliferation, we investigated the effects of calcium channel-blocking agents on the growth of meningioma cells in vitro. Primary meningioma cell cultures were established, and the cells were characterized by light and electron microscopy and by immunohistochemical studies. Then, the cultures were given growth factors and/or various calcium channel antagonists, and growth rates were measured. A dose-response decrease in cell growth was seen when verapamil, nifedipine, or diltiazem (voltage-dependent calcium channel-blocking agents) was added to serum-containing media. Also, these drugs blocked the growth stimulation of epidermal growth factor and platelet-derived growth factor in a similar fashion. Dantrolene, which inhibits the release of sequestered intracellular calcium, was also an effective blocker of the mitogenic stimulation of these growth factors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7731518     DOI: 10.1227/00006123-199502000-00017

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  11 in total

1.  In vitro growth inhibition of human colonic tumor cells by Verapamil.

Authors:  Qi-Zhen Cao; Gang Niu; Huan-Ran Tan
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

Review 2.  Platelet-derived growth factor in human brain tumors.

Authors:  M Kirsch; J C Wilson; P Black
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

3.  Phenotypic change of human cultured meningioma cells.

Authors:  R Pallini; P Casalbore; D Mercanti; N Maggiano; L M Larocca
Journal:  J Neurooncol       Date:  2000-08       Impact factor: 4.130

Review 4.  Aberrant signaling pathways in meningiomas.

Authors:  Brian T Ragel; Randy L Jensen
Journal:  J Neurooncol       Date:  2010-09-14       Impact factor: 4.130

Review 5.  The biology of meningiomas.

Authors:  I E McCutcheon
Journal:  J Neurooncol       Date:  1996-09       Impact factor: 4.130

6.  Molecular biology of unreresectable meningiomas: implications for new treatments and review of the literature.

Authors:  Jay Jagannathan; Rod J Oskouian; Hian Kwang Yeoh; Dwight Saulle; Aaron S Dumont
Journal:  Skull Base       Date:  2008-05

7.  Ion channel blockers and glioblastoma risk and outcome: a nested case-control and retrospective cohort studies.

Authors:  Ben Boursi; Harry J Han; Kevin Haynes; Ronac Mamtani; Yu-Xiao Yang
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-07-07       Impact factor: 2.890

Review 8.  Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas.

Authors:  Chrissa Sioka; Athanassios P Kyritsis
Journal:  J Neurooncol       Date:  2008-11-21       Impact factor: 4.130

Review 9.  Repurposing of Anticancer Stem Cell Drugs in Brain Tumors.

Authors:  Hisham F Bahmad; Darine Daher; Abed A Aljamal; Mohamad K Elajami; Kei Shing Oh; Juan Carlos Alvarez Moreno; Ruben Delgado; Richard Suarez; Ana Zaldivar; Roshanak Azimi; Amilcar Castellano; Robert Sackstein; Robert J Poppiti
Journal:  J Histochem Cytochem       Date:  2021-06-24       Impact factor: 2.479

Review 10.  The prince and the pauper. A tale of anticancer targeted agents.

Authors:  Alfonso Dueñas-González; Patricia García-López; Luis Alonso Herrera; Jose Luis Medina-Franco; Aurora González-Fierro; Myrna Candelaria
Journal:  Mol Cancer       Date:  2008-10-23       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.